{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:24:03Z","timestamp":1785583443872,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK 56942"],"award-info":[{"award-number":["DK 56942"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.labinv.2023.100305","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T19:39:43Z","timestamp":1702755583000},"page":"100305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease"],"prefix":"10.1016","volume":"104","author":[{"given":"Tareq","family":"Al Tuhaifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-7492","authenticated-orcid":false,"given":"Hai-Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-8527","authenticated-orcid":false,"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.labinv.2023.100305_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.04.055","article-title":"Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy","volume":"761","author":"Jung","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.labinv.2023.100305_bib2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.labinv.2023.100305_bib3","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.2215\/CJN.02030311","article-title":"Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality","volume":"6","author":"Muntner","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.labinv.2023.100305_bib4","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.2337\/db13-0305","article-title":"Transforming growth factor-beta-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy","volume":"62","author":"Deshpande","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.labinv.2023.100305_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00041552-199405000-00004","article-title":"Epidemiology of microalbuminuria in diabetes and in the background population","volume":"3","author":"Mogensen","year":"1994","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.labinv.2023.100305_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","article-title":"Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study","volume":"156","author":"Ravid","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.labinv.2023.100305_bib7","first-page":"S150","article-title":"Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria","volume":"45","author":"Lebovitz","year":"1994","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.labinv.2023.100305_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.hjh.0000191244.91314.9d","article-title":"Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes","volume":"24","author":"Burnier","year":"2006","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.labinv.2023.100305_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.labinv.2023.100305_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.ackd.2014.04.001","article-title":"Mechanisms of disease reversal in focal and segmental glomerulosclerosis","volume":"21","author":"Yang","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.labinv.2023.100305_bib11","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.labinv.2023.100305_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.labinv.2023.100305_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3132\/dvdr.2006.024","article-title":"Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes","volume":"3","author":"Green","year":"2006","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.labinv.2023.100305_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.labinv.2023.100305_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0065-1281(11)80085-1","article-title":"Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney","volume":"92","author":"Kettmann","year":"1992","journal-title":"Acta Histochem"},{"key":"10.1016\/j.labinv.2023.100305_bib16","doi-asserted-by":"crossref","first-page":"R897","DOI":"10.1152\/ajpregu.00569.2006","article-title":"Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation","volume":"292","author":"Boerrigter","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.labinv.2023.100305_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1507\/endocrj.K10E-382","article-title":"Sitagliptin reduces albuminuria in patients with type 2 diabetes","volume":"58","author":"Hattori","year":"2011","journal-title":"Endocr J"},{"key":"10.1016\/j.labinv.2023.100305_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000341487","article-title":"DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy","volume":"36","author":"Alter","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.labinv.2023.100305_bib19","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1681\/ASN.2006070798","article-title":"Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice","volume":"17","author":"Zhao","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.labinv.2023.100305_bib20","doi-asserted-by":"crossref","first-page":"F911","DOI":"10.1152\/ajprenal.00037.2005","article-title":"Meprin-alpha in chronic diabetic nephropathy: interaction with the renin\u2013angiotensin axis","volume":"289","author":"Mathew","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.labinv.2023.100305_bib21","doi-asserted-by":"crossref","first-page":"F590","DOI":"10.1152\/ajprenal.00324.2003","article-title":"Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance","volume":"286","author":"Qi","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.labinv.2023.100305_bib22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1681\/ASN.2004060492","article-title":"Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1","volume":"16","author":"Ma","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.labinv.2023.100305_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00441-015-2178-8","article-title":"Alteration in the podoplanin-ezrin-cytoskeleton linkage is an important initiation event of the podocyte injury in puromycin aminonucleoside nephropathy, a mimic of minimal change nephrotic syndrome","volume":"362","author":"Suzuki","year":"2015","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.labinv.2023.100305_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00592-014-0640-9","article-title":"Prediction of 90-day mortality in patients without diabetes by severe hypoglycemia: blood glucose level as a novel marker of severity of underlying disease","volume":"52","author":"Tsujimoto","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.labinv.2023.100305_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.labinv.2023.100305_bib26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.labinv.2023.100305_bib27","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1111\/dom.13441","article-title":"Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats","volume":"20","author":"Jaikumkao","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.labinv.2023.100305_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.labinv.2023.100305_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.labinv.2023.100305_bib30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A\u00a0sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.labinv.2023.100305_bib31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.labinv.2023.100305_bib32","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.labinv.2023.100305_bib33","doi-asserted-by":"crossref","first-page":"F480","DOI":"10.1152\/ajprenal.00214.2007","article-title":"Targeted disruption of the meprin metalloproteinase beta gene protects against renal ischemia-reperfusion injury in mice","volume":"294","author":"Bylander","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.labinv.2023.100305_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.labinv.2023.100305_bib35","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.labinv.2023.100305_bib36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4158\/EP-2020-0143","article-title":"Dipeptidyl-peptidase 4 inhibitors did not improve renal endpoints in advanced diabetic kidney disease","volume":"26","author":"Kornelius","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.labinv.2023.100305_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/895102","article-title":"Renal effects of DPP-4 inhibitors: a focus on microalbuminuria","volume":"2013","author":"Haluzik","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.labinv.2023.100305_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db11-1667","article-title":"Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli","volume":"62","author":"Hodgin","year":"2013","journal-title":"Diabetes"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683723002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683723002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:00:36Z","timestamp":1758398436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683723002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0023683723002489"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2023.100305","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2023.100305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100305"}}